Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 5, 1996, Pages 543-553

  Hartigan Go, Kenneth ^b   Bateman, D Nicholas ^c   Nyberg, Gösta ^c   Mårtensson, Erik ^c   Thomas, Simon H L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PLACEBO; THIORIDAZINE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; ELECTROCARDIOGRAM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029801375     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90150-2     Document Type: Article

References (43)

1. Thomas SHL. Drugs, QT interval prolongation and ventricular arrhythmias. Adverse Drug React Toxicol Rev 1994;13:77-102.
2. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239-45.
3. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-9.
4. Ban TA, St Jean A. Electrocardiographic changes induced by phenothiazine drugs. Am Heart J 1965;70: 575-6.
5. Huston JR, Bell GE. The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogram. JAMA 1966;198:16-20.
6. Burda CD. Electrocardiographic abnormalities induced by thioridazine (Mellaril). Am Heart J 1968;76: 153-6.
7. Fletcher GF, Kazamias TM, Wenger NK. Cardiotoxic effects of melleril: conduction disturbances and supraventricular arrhythmias. Am Heart J 1960;78: 135-8.
8. Alvarez-Mena S, Frank M. Phenothiazine-induced T-wave abnormalities: effects of overnight fasting. JAMA 1973;224:730-3.
9. Kelly HQ, Fay JE, Laverty FG. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report on two fatalities with electrographic abnormalities. Can Med Assoc J 1963;89:546-54.
10. Desautels S, Filteau C, St Jean A. Ventricular tachycardia associated with administration of thioridazine hydrochloride (Mellaril). Can Med Assoc J 1964;90: 1030-1.
11. Hollister LE, Kosik JC. Sudden death during treatment with phenothiazine derivatives. JAMA 1965; 192:1035-8.
12. Schoonmaker FW, Osteen RT, Greenfield JC. Thioridazine (Mellaril)-induced ventricular tachycardia controlled with an artificial pacemaker. Ann Intern Med 1966;65:1076-8.
13. Giles T, Modlin R. Death associated with ventricular arrhythmias and thioridazine hydrochloride. JAMA 1968;205:98-100.
14. Alexander CS, Nino A. Cardiovascular complications in young patients taking psychotropic drugs: a preliminary report. Am Heart J 1969;78:757-69.
15. Sydney MA. Ventricular arrhythmias associated with use of thioridazine hydrochloride in alcohol withdrawal. Br Med J 1973;24:476.
16. Fowler N, McCall D, Chou T, Holmes JC, Hanenson IB. Electrographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 1976;37:223-30.
17. Kemper A. Thioridazine-induced torsade de pointes. Successful therapy with isoprotenerol. JAMA 1983; 249:2931-4.
18. Kiriike N, Maeda Y, Nishiwaki S, Izumiya Y, Katahara S, Mui K, et al. Iatrogenic torsade de pointes induced by thioridazine. Biol Psychiatry 1987;22:99-103.
19. Arita M, Surawicz B. Electrophysiologic effects of thioridazine on canine cardiac fibers. J Pharmacol Exp Ther 1973;184:619-30.
20. Yoon MS, Han J, Dersham GH, Jones SA. Effects of thioridazine (Melleril) on ventricular electrophysiologic properties. Am J Cardiol 1979;43:1155-8.
21. Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common with thioridazine overdose than with other neuroleptics. Clin Toxicol 1995;33:199-204.
22. Mehtonen OP, Aranko K, Malkonen L, Vapaatalo H. Survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991;84:58-64.
23. Axelsson R, Aspenstrom G. Electrocardiographic changes and serum concentrations in thioridazine-treated patients. J Clin Psychiatry 1982;43:332-5.
24. Dollery CT, Davies DS, Draffan GH, Dargie HJ, Dean CR, Reid JL, et al. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 1976;19:11-7.
25. Hindmarch I. Some aspects of the effects of clobazam in human psychomotor performance. Br J Clin Pharmacol 1979;7:775-825.
26. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47: 211-8.
27. Daly AK, Armstrong M, Monkman SG, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991;1:33-41.
28. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Methods Enzymol 1996;272: 199-210.
29. von Bahr C, Movin G, Nordin C, Lidèn A, Hammarlund-Udenaes M, Hedberg A, et al. Plasma levels of thioridazine and metabolites are influenced by debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991;49:234-40.
30. Axelsson R. On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine side-chain sulfone in chronic psychotic patients. Curr Ther Res 1977;21: 587-605.
31. Hubbard JW, Midha KK, Hawes EM, McKay G, Marder SR, Aravagiri M, et al. Metabolism of phenothiazine and butyrophenone antipsychotic drugs: a review of some recent research findings and clinical implications. Br J Psychiatry 1993;163 (suppl 22): 19-24.
32. Axelsson R, Mårtensson E. Serum concentration and elimination from serum of thioridazine in psychiatric patients. Curr Ther Res 1976;19:242-65.
33. Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther 1991;5:515-30.
34. Thomas SHL, Higham PD, Hartigan-Go K, Kamali F, Wood P, Campbell RWF, et al. Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 1995;74:53-6.
35. Hartigan-Go K, Bateman DN, Daly AK, Thomas SHL. Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 1996;60:89-98.
36. Bylund DB. Interactions of neuroleptic metabolites with dopaminergic, alpha-adrenergic and muscarinic cholinergic receptors. J Pharmacol Exp Ther 1981; 217:81-6.
37. Axelsson R, Mårtensson E. Side effects of thioridazine and their relationship with the serum concentrations of the drug and its main metabolites. Curr Ther Res 1980;28:463-89.
38. Papadopoulos AS, Chand TG, Crammer JL, Lader S. A pilot study of plasma thioridazine and metabolites in chronically treated patients. Br J Psychiatry 1980; 136:591-6.
39. Hale PW, Poklis A. Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol Appl Pharmacol 1986;86:44-55.
40. Heath A, Svensson C, Mårtensson E. Thioridazine toxicity: an experimental cardiovascular study of thioridazine and its major metabolites in overdose. Vet Hum Toxicol 1985;2:100-5.
41. Nyberg G, Axelsson R, Mårtensson E. Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. Eur J Clin Pharmacol 1978;14:341-50.
42. Jortani SA, Poklis A. Determination of thioridazine enantiomers in human serum by sequential achiral and chiral high-performance liquid chromatography. J Anal Toxicol 1993;17:374-7.
43. Svendsson CN, Froimowitz M, Hrbek C, Campbell A, Kula N, Baldessarini RJ, et al. Receptor affinity, neurochemistry and behavioural characteristics of the enantiomers of thioridazine: evidence for different stereoselectivities at D1 and D2 receptors in rat brain. Neuropharmacology 1988;27:1117-24.